title: 5-day vinblastine infusion for pancreatic adenocarcinoma. A phase II Southwest Oncology Group study.
authors.affiliation: Southwest Oncology Group Statistical Center, Seattle.
authors.forename: J T
authors.initials: JT
authors.lastname: Guy
authors.forename: T
authors.initials: T
authors.lastname: Fleming
authors.forename: T W
authors.initials: TW
authors.lastname: Pollock
authors.forename: S E
authors.initials: SE
authors.lastname: Rivkin
authors.forename: R P
authors.initials: RP
authors.lastname: Pugh
authors.forename: H
authors.initials: H
authors.lastname: Saiers
authors.forename: H E
authors.initials: HE
authors.lastname: Hynes
authors.forename: J F
authors.initials: JF
authors.lastname: Boyd
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000380:Agranulocytosis / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014747:Vinblastine